The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Open accessAbstract
BACKGROUND: Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks. OBJECTIVE: We sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III AD studies (AD-301: NCT02118766; AD-302: NCT02118792). METHODS: Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days. The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline. Additional analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, reduction in severity of AD signs, and time to improvement in pruritus. RESULTS: More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001). Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001). Treatment-related adverse events were infrequent and mild to moderate in severity. LIMITATIONS: Short study duration was a limitation. CONCLUSIONS: Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase Three
Odhiambo, J. A., Williams, H. C., Clayton, T. O., Robertson, C. F., & Asher, M. I. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.009 · Cited by 966
Bieber, T. (2010) · Annals of Dermatology · doi:10.5021/ad.2010.22.2.125 · Cited by 557
Atopic dermatitis: A practice parameter update 2012
Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417
Self-citationMediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 353
Berth-Jones, J., Damstra, R. J., Golsch, S., Livden, J. K., Van Hooteghem, O., Allegra, F., & Parker, C. A. (2003) · BMJ · doi:10.1136/bmj.326.7403.1367 · Cited by 320
Persistence of Mild to Moderate Atopic Dermatitis
Margolis, J. S., Abuabara, K., Bilker, W., Hoffstad, O., & Margolis, D. J. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.10271 · Cited by 276
Invited Review Article : Atopic Dermatitis
Bieber, T. R. M. (2010) · Annals of Dermatology · Cited by 255
Grewe, S. R., Chan, S. C., & Hanifin, J. M. (1982) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(82)90008-2 · Cited by 230
Hanifin, J. M., Chan, S. C., Cheng, J. B., Tofte, S. J., Henderson, W. R., Kirby, D. S., & Weiner, E. S. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12297888 · Cited by 229
Akama, T., Baker, S. J., Zhang, Y.-K., Hernandez, V., Zhou, H., Sanders, V., Freund, Y., Kimura, R., Maples, K. R., & Plattner, J. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.007 · Cited by 218
Cost of atopic dermatitis and eczema in the United States
Ellis, C. N., Drake, L. A., Prendergast, M. M., Abramovits, W., Boguniewicz, M., Daniel, C. R., Lebwohl, M., Stevens, S. R., Whitaker-Worth, D. L., Cheng, J. W., et al. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120528 · Cited by 211
Self-citationA systematic review of the safety of topical therapies for atopic dermatitis
Callen, J., Chamlin, S., Eichenfield, L. F., Ellis, C., Girardi, M., Goldfarb, M., Hanifin, J., Lee, P., Margolis, D., Paller, A. S., et al. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07538.x · Cited by 199
Self-citationTopical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
Carr, W. W. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0013-9 · Cited by 177
What causes itch in atopic dermatitis?
Yosipovitch, G., & Papoiu, A. D. P. (2008) · Current Allergy and Asthma Reports · doi:10.1007/s11882-008-0049-z · Cited by 168
Management of Difficult-to-Treat Atopic Dermatitis
Arkwright, P. D., Motala, C., Subramanian, H., Spergel, J., Schneider, L. C., & Wollenberg, A. (2013) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2012.09.002 · Cited by 167
Baumer, W., Hoppmann, J., Rundfeldt, C., & Kietzmann, M. (2007) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152807780077318 · Cited by 162
Butler, J. M., Chan, S. C., Stevens, S. R., & Hanifin, J. M. (1983) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(83)90467-0 · Cited by 143
Siegfried, E. C., Jaworski, J. C., & Hebert, A. A. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0020-1 · Cited by 139
Self-citationWittmann, M., & Helliwell, P. (2013) · Dermatology and Therapy · doi:10.1007/s13555-013-0023-0 · Cited by 132
Jiménez, J. L., Punzón, C., Navarro, J., Muñoz‐Fernández, M. Á., & Fresno, M. (2001) · PubMed · Cited by 115
Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center
Freund, Y. R., Akama, T., Alley, M. R. K., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.058 · Cited by 113
Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar, S. G., Rajagopal, D., & Ray, A. (2007) · PubMed · Cited by 105
Schachner, L. A., Lamerson, C. L., Sheehan, M. P., Boguniewicz, M., Mosser, J. L., Raimer, S., Shull, T., Jaracz, E., & for the US Tacrolimus Ointment Study Group (2005) · PEDIATRICS · doi:10.1542/peds.2004-2638 · Cited by 84
Self-citationZane, L. T., Kircik, L., Call, R. S., Tschen, E. H., Draelos, Z. D., Chanda, S., Syoc, M. V., & Hebert, A. A. (2016) · Pediatric Dermatology · doi:10.1111/pde.12872 · Cited by 80
Self-citationCrisaborole and its Potential Role in Treating Atopic Dermatitis: Overview of Early Clinical Studies
Zane, L. T., Chanda, S., Jarnagin, K., Nelson, D., Spelman, L. J., & Gold, L. S. (2016) · Immunotherapy · doi:10.2217/imt-2016-0023 · Cited by 77
Self-citationTom, W. L., Syoc, M. V., Chanda, S., & Zane, L. T. (2016) · Pediatric Dermatology · doi:10.1111/pde.12780 · Cited by 76
Self-citationAN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian, R., & Weinberg, J. M. (2009) · PubMed · Cited by 74
Update on the management of chronic eczema: new approaches and emerging treatment options
Walling, H. W., & Swick, B. L. (2010) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s6496 · Cited by 70
Jiménez, J. L., Punzón, C., Navarro, J., Muñoz‐Fernández, M. Á., & Fresno, M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29287-9 · Cited by 68
Murrell, D. F., Gebauer, K., Spelman, L. J., & Zane, L. T. (2015) · PubMed · Cited by 65
Self-citationHeskel, N. S., Chan, S. C., Thiel, M. L., Stevens, S. R., Casperson, L. S., & Hanifin, J. M. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)70184-8 · Cited by 64
Sobell, J. M., Foley, P. J., Toth, D., Mrowietz, U., Girolomoni, G., Gonçalves, J., Day, R. M., Chen, R., & Yosipovitch, G. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2360 · Cited by 63
Gold, L. S., Spelman, L. J., Spellman, M. C., Hughes, M. H., & Zane, L. T. (2015) · PubMed · Cited by 63
Self-citationAtopic dermatitis in children: management of pruritus
Blume‐Peytavi, U., & Metz, M. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04710.x · Cited by 47
Zuberbier, T. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04185.x · Cited by 42
Andoh, T., Yoshida, T., & Kuraishi, Y. (2014) · Experimental Dermatology · doi:10.1111/exd.12377 · Cited by 36
Advances in therapeutic strategies for the treatment of pruritus
Stull, C. M., Lavery, M. J., & Yosipovitch, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1127355 · Cited by 36
Phosphodiesterase and immune dysfunction in atopic dermatitis
Hanifin, J. M. (1990) · Journal of Dermatological Science · doi:10.1016/0923-1811(90)90003-v · Cited by 30
Jiménez, J. L., Iñiguez, M. A., Muñoz‐Fernández, M. Á., & Fresno, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.002 · Cited by 29
Wakita, H., Ohkuro, M., Ishii, N., et al. (2014) · Experimental Dermatology · doi:10.1111/exd.12606 · Cited by 24
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
“Moreover, two identically designed, vehicle-controlled, double-blind studies suggested that crisaborole-treated patients manifested great improvement in Investigator’s Static Global Assessment (ISGA) score, and treatment-associated side effects were mild-to-moderate (Paller et al., 2016).”
BackgroundWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Self-citation
Metadata
- Authors
- Paller, A. S., Tom, W. L., Lebwohl, M. G., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., Spellman, M. C., Stein Gold, L. F., Zaenglein, A. L., Hughes, M. H., Zane, L. T., & Hebert, A. A.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 75
- Issue
- 3
- Pages
- 494-503.e6
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2471976905
- Cited by
- 577
- References
- 44
- FWCI
- 64.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.